Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 7, 2022; 28(29): 3869-3885
Published online Aug 7, 2022. doi: 10.3748/wjg.v28.i29.3869
Published online Aug 7, 2022. doi: 10.3748/wjg.v28.i29.3869
Figure 5 Western blot validations of potential glycoprotein biomarkers.
A and B: Representative Western blot results show haptoglobin (HP) (A) and procathepsin D (pCD) (B) with differential expression between esophageal squamous cell carcinoma (ESCC/T) and adjacent non-cancerous tissues (N); C: Representative Western blot results show the N-linked glycosylated fraction of HP, pCD, clusterin, superoxide dismutase 3 (SOD3), proline-arginine-rich end leucine-rich repeat protein (PRELP), and 14-3-3ζ in ESCC/T and N enriched by corresponding lectins; D: Representative Western blot results show the N-linked glycosylated fractions of clusterin, PRELP, and HP in serum of patients with ESCC/T and healthy controls. The results are representative of three independent experiments. ESCC/T: Esophageal squamous cell carcinoma; HP: Haptoglobin; pCD: Procathepsin D; SOD3: Superoxide dismutase 3; PRELP: Proline-arginine-rich end leucine-rich repeat protein.
- Citation: Liu QW, Ruan HJ, Chao WX, Li MX, Jiao YL, Ward DG, Gao SG, Qi YJ. N-linked glycoproteomic profiling in esophageal squamous cell carcinoma. World J Gastroenterol 2022; 28(29): 3869-3885
- URL: https://www.wjgnet.com/1007-9327/full/v28/i29/3869.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i29.3869